Navigation Links
Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
Date:4/18/2008

NEW YORK, April 18 /PRNewswire/ -- Armed with over 30 years of experience in slimming products, Biotherm biologists have made a new discovery set to revolutionize cosmetic treatments for stubborn cellulite. This spring, Biotherm launches CELLULI LASER(TM), a unique three-step system consisting of a scrub, massage tool and treatment gel providing visible, 10 day results in 71% of the women tested**.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080418/AQF014)

Inspired by the astounding results laser techniques produce on the skin, Biotherm's new CELLULI LASER treatment gel contains BIOFIBRINE(TM), an exclusive Biotherm technology that targets fibers to help stimulate production of collagen*.

"The idea underlying the BIOFIBRINE(TM) complex was inspired by the way lasers work," explains Dr. Blanchemaison, a specialist in vascular medicine and Director of Studies at the University of Paris V Medical School. Dr. Blanchemaison is also the author of Conquering Cellulite.

Biotherm biologists have discovered that when collagen fibers are flexible, the appearance of cellulite is reduced. The BIOFIBRINE complex is a combination of Carbocysteine and Biopeptides. Carobcystiene has anti-glycation properties that help collagen fiber from becoming hard. The biopeptides help stimulate new collagen production*. Other ingredients such as caffeine, ginkgo, ginseng, and cola nut -- all found in the new CELLULI LASER products -- also help to contribute to the reduction of the appearance of cellulite.

How do the treatments work?

The warming and exfoliating texture of CELLULI LASER SCRUB targets unattractive "orange peel" bumps and bulges that sometimes appear on the legs, stomach and arms. Designed for application on dry skin, the texture is suggested as the first step of the treatment. Next, by facilitating a professional style kneading massage from the comfort
'/>"/>

SOURCE Biotherm
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
2. ARUP Laboratories CEO and Co-Founder Announces Retirement
3. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
6. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
7. Angiotech announces director resignation
8. BioHorizons Announces the Purchase of Implant Logic Systems
9. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
10. Arpida Announces Conference Call on 17 April
11. Arpida Announces Agenda Items for Shareholders Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolyti...s" or the "Company") today announced updated resul...) in patients with sarcomas metastatic to the lung...ctive Tissue Oncology Society Meeting held in Miam...ster presentation, entitled "A Phase II Study of I...
(Date:11/6/2009)... The agenda for Arrowhead&rsqu...ence, which is set to take place on February 22-24...s three day conference we will highlight key issue...kers to share their experiences. , ... -- The agenda for Arrowhead’s 2010 Persona...
(Date:11/5/2009)... GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ ...ts financial results for the third quarter ended S...3.6 million ($0.04 per share) for the three months...f $6.8 million ($0.08 per share) in the comparable...ber 30, 2009, GenVec,s net loss was $14.1 million ...
(Date:11/5/2009)... PARSIPPANY, N.J., Nov. 5 DSM Phar...de a manufacturing alliance with Galenix, Saint Je...d commercial scale manufacturing partner for Galen...M and Galenix will collaborate on business develop...ery technologies, based on the strength of Galenix...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
... Calif., July 31 Alsius Corporation,(Nasdaq: ALU...ture,management (IVTM(TM)) therapies for criticall...a conference call to discuss the Company,s,second ...ll Worthen,president and CEO, will host the call b...ern Time) on Thursday, August 7. A press release f...
... Colo., July 31 Sierra Neuropharmaceuticals,Inc.,...-brain treatment of,neurological diseases, announc...ing. Co-leads in the funding were HealthCare Ventu...tners. Other investors include High Country,Ventur...etary drug development process that makes use of,s...
...OWN, Pa., July 31 The Quigley,Corporation (Nasdaq...,operations of $2.1 million, for the second quarte...orted for the second quarter ended June 30,2007. F...ere $7.4 million,compared to $8.4 million reported...t sales were influenced by distribution changes an...
Other Biology Technology:Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 2The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 4The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 5The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 6
(Date:11/9/2009)... Naturwissenschaften is publishing a special issu...ology" to commemorate Darwin,s On the Origin of Sp...r 1859. Guest editor and author of the lead articl...iology and evolutionary biology at the University ... issue are available free of charge until 30 Decem...
(Date:11/9/2009)..., November 09, 2009 / b3c newswire / - Today, T...venth Wave, an American organization for contract ...ies have signed a letter of intent with regard to ...M. The letter of intent proposes a collaboration i...or commercialization in North America. The TIM sys...
(Date:11/8/2009)...d. - Researchers at Purdue University have discove...ers in spinal cord injuries using nano-spheres tha...n accident. , The synthetic "copolymer micelles"...diameter, or roughly 100 times smaller than the di...een studying how to deliver drugs for cancer treat...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 1AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 2AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 3Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 1Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 2Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 3Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 4Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 5Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 6Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28 2009 13135 1Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28 2009 13135 2
... nutritious and tasty, but don’t count on them to ...er Epidemiology, Biomarkers & Prevention, rese... Fred Hutchinson Cancer Research Center report tha...tomatoes, does not effectively prevent prostate ca...on between beta-carotene, an antioxidant related t...
... Universitat Autònoma de Barcelona (UAB), in coope...-chemical biosensor which detects the presence, in...he most widely used herbicides in agriculture and ...vironment- as well as antibiotics in food. The bio...the expensive laboratory methods which are used to...
...ar symmetrical at first glance, but we,re full of ... up a pencil or throw a baseball, to where languag... our internal organs, humans are a glut of asymmet...norhabditis elegans has nerves on its left and rig...ndedness, the determination of which nerves develo...
Other Biology News:No magic tomato? Study breaks link between lycopene and prostate cancer prevention 2A new portable biosensor detects traces of contaminants in food more quickly and cheaply 2Left-right wiring determined by neural communication in the embryonic worm 2
Rabbit Anti-Human DNase II Polyclonal Antibody, Unconjugated from Calbiochem
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes from BD Biosciences - Discovery Labware
BD BioCoat Collagen I 60 mm Culture Dishes from BD Biosciences - Discovery Labware
Corning C ulture Dishes,100X20 mm,55Cm2,Sterile,6-Pack Carrier (6Pks Of 10 Dishes) from Sigma-Aldrich
Biology Products: